Immutep presents two posters at ESMO on changing landscape for 1L NSCLC

Immutep (IMMP) announces two poster presentations at the European Society for Medical Oncology Congress 2025 highlight the Company’s focus on changing the treatment paradigm in first line non-small cell lung cancer. Data from the investigator-initiated INSIGHT-003 trial with a cut-off date of 01 September 2025 were detailed in a poster presented by Dr. med. Akin Atmaca, Head of the Thoracic Oncology, Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt, Germany. In this multi-centre study, the novel combination of eftilagimod alfa with KEYTRUDA and chemotherapy has generated strong objective response rates and disease control rates in 51 evaluable patients with advanced or metastatic non-squamous 1L NSCLC across all PD-L1 expression levels. Notably, the ORR and DCR reported in INSIGHT-003 outperforms historical controls irrespective of PD-L1 levels. This is particularly important for patients with low and no PD-L1, who represent over two-thirds of the 1L NSCLC patient population and for whom PD-(L)1 inhibitors typically perform suboptimally. In patients with TPS less than50%, the combination with efti has achieved a strong and improved 61.7% ORR as compared to historical control of 40.8%. Further to the strong efficacy data from INSIGHT-003, the combination with efti continues to have a favourable safety profile. Additionally, a Trial in Progress ePoster for the TACTI-004 Phase III was presented at ESMO Congress 2025. This registrational trial is evaluating the same immunotherapy/chemotherapy combination used in INSIGHT-003. This global study will enrol approximately 756 patients with advanced/metastatic 1L NSCLC regardless of PD-L1 expression with non-squamous or squamous tumours at over 150 clinical sites in over 25 countries. The poster for INSIGHT-003 and the Trial in Progress ePoster for TACTI-004 can be found at the Posters & Publications section of Immutep’s website.